



**EHRA**  
European Heart  
Rhythm Association

## Application for Membership of the Nominating Committee (2026–2028)



Professor

DEHARO

Jean-Claude



CHU La Timone - Marseille

Cardiology

Boulevard Jean Moulin

13005 Marseille - France



**EHRA**  
European Heart  
Rhythm Association



**ESC**  
European Society  
of Cardiology



## 2. General Curriculum Vitae (300 words max)- Please add your H index and top 10 publications in the last 5 years

**Jean-Claude Deharo, MD, FESC**

**Address:** CHU La Timone, Cardiology Department, Rue Saint Pierre, 13005 Marseille, France

**Email:** [jean-claude.deharo@ap-hm.fr](mailto:jean-claude.deharo@ap-hm.fr)

**Affiliations :** Assistance Publique – Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France and Aix Marseille Université, C2VN, Marseille, France

French cardiologist, electrophysiology specialist

Full Professor of Cardiology at Aix-Marseille Université, Marseilles Medical School since 1998.

Head of the arrhythmia department of La Timone Academic Hospital of Marseilles which is a thousand bed academic hospital.

Area of expertise: syncope, cardiac pacing and defibrillation, resynchronization therapy, leadless pacing, lead extractions, ablation of arrhythmias.

### **Activities in guidelines and consensus document task forces**

Involved in several ESC guidelines task forces and several EHRA and HRS consensus documents in the field of cardiac pacing, syncope, device and lead management, resynchronization therapy and conduction system pacing

### **Publication activities:**

More than 275 publications in peer reviewed journals, in the field of arrhythmology (syncope, cardiac pacing and electrophysiology, lead extraction...). H-index: 39.

1. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabés JA, Boriani G, Braunschweig F, Brignole M, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). *European Heart Journal*. 2021;42:3427-3520. doi: 10.1093/eurheartj/ehab364
2. Maille B, Bodin A, Bisson A, Herbert J, Pierre B, Clementy N, Klein V, Franceschi F, Deharo JC, Fauchier L. Predicting outcome after cardiac resynchronisation therapy defibrillator implantation: the cardiac resynchronisation therapy defibrillator Futility score. *Heart*. 2022;108:1186-1193. doi: 10.1136/heartjnl-2021-320532
3. Maille B, Bouchat M, Dognin N, Deharo P, Ressayguier N, Franceschi F, Koutbi-Franceschi L, Hourdain J, Martinez E, Zabern M, et al. Advantages and disadvantages of drug challenge during electrophysiological study in patients with new left bundle branch block after transaortic valve implantation. *Int J Cardiol Heart Vasc*. 2022;39:100961. doi: 10.1016/j.ijcha.2022.100961
4. Guieu R, Fromonot J, Mottola G, Maille B, Marlinge M, Gropelli A, Conte S, Bechah Y, Lalevee N, Michelet P, et al. Adenosinergic System and Neuroendocrine Syncope: What Is the Link? *Cells*. 2023;12. doi: 10.3390/cells12162027



5. Fedorowski A, Kulakowski P, Brignole M, de Lange FJ, Kenny RA, Moya A, Rivasi G, Sheldon R, Van Dijk G, Sutton R. Twenty-five years of research on syncope. *Europace*. 2023;25:euad163.
6. Maille B, Behar N, Jacon P, Hourdain J, Franceschi F, Koutbi L, Tovmassian L, Bierme C, Seder E, Klein V. Two-in-one procedure for transvenous lead extraction and leadless pacemaker reimplantation in pacemaker-dependent patients with device infection: streamlined patient flow. *Europace*. 2024;26:euae162.
7. Deharo J-C, Essayagh B, Sabbag A. Rethinking Risk in Mitral Valve Prolapse: The Promise of Machine Learning and Multimodal Phenotyping. In: American College of Cardiology Foundation Washington DC; 2025.
8. Groppelli A, Russo V, Parente E, Comune A, de Lange FJ, Rivasi G, Rafanelli M, Deharo JC, Francisco-Pascual J, Maggi R. Mechanism of syncope: role of ambulatory blood pressure monitoring and cardiovascular autonomic function assessment. *European Heart Journal*. 2025;46:827-835.
9. Fiorina L, Carbonati T, Maille B, Narayanan K, Porquet P, Henry C, Singh JP, Marijon E, Deharo J-C. Deep Learning Can Unmask Conduction Tissue Disease From an Ambulatory ECG. *Circulation: Arrhythmia and Electrophysiology*. 2025;18:e013695. doi: doi:10.1161/CIRCEP.124.013695
10. Deharo J-C, Dreyfus J, Bongiorno M-G, Burri H, Defaye P, Glikson M, Lever N, Mangieri A, Mondésert B, Nielsen JC, et al. Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society. *EP Europace*. 2025;27. doi: 10.1093/europace/euaf061



**EHRA**  
European Heart  
Rhythm Association



**ESC**  
European Society  
of Cardiology



### 3. Describe previous experience(s) within EHRA, ESC or your National Cardiac Society

#### **Activities in ESC and EHRA**

ESC member since 1999

Member of the Working Group of Cardiac Pacing since 2000, which became EHRA in 2003

ESC Fellow since 2007

Current member of the DOI committee of the ESC

Former member and co-chair of the EHRA Accreditation committee,

Former member of the EHRA Nominating Committee

Former member of the EHRA Scientific Documents Committee

Former chair of the EHRA patients' committee, currently member of the committee

Former member of the board of EHRA

Current member of the board of Europace journal, Deputy editor of the Syncope section

#### **Activities in the French Society of Cardiology**

Member of the French Society of Cardiology since 1990

Former President of the frenchworking group of cardiac pacing and electrophysiology

Member of the board of the French Society of Cardiology since 2020

Current General Secretary of the French Society of Cardiology

Elected next vice-president of the French Society of Cardiology (term starting in january 2026)



#### 4. Why are you motivated to join the EHRA Executive Board (250 words max)?

I am strongly motivated to serve as a member of the EHRA Nominating Committee.

Having been actively involved in the field of cardiac electrophysiology for more than 35 years, and as an engaged member of EHRA, I am deeply committed to contributing to the fair selection of future members for key positions within our Association.

Throughout my professional career, I have had the privilege of working in both clinical and academic environments, with a focus on electrophysiology and device therapy.

My involvement in EHRA activities, including serving as a member of the Board, has strengthened my conviction that individuals holding key positions within EHRA are essential in guiding the Association's strategic direction and long-term vision.

I firmly believe that the Nominating Committee plays a crucial role in upholding these values.

As a member, I would bring a balanced perspective that combines clinical experience, academic rigor, and a truly European outlook.

I would be particularly committed to maintaining EHRA's vitality, visibility, and excellence within the international electrophysiology community.

I am eager to contribute to a transparent and fair selection process that identifies and supports the most qualified individuals to serve our community.

It would be an honour to collaborate with esteemed colleagues in shaping the future of EHRA.

Thank you for considering my application.



## 5. How will you combine your EHRA position with your daily clinical/research workload?

Please note that we expect you to:

- Have an active career at the time of taking office
  - Be on clinical practice (for at least 30%) at the time of application
- 

I will remain in active professional practice during the 2026–2028 term. Having previously served as a member of the Nominating Committee, I am fully aware of the workload involved and will devote as much time as necessary while continuing my regular clinical activity.



## 6. Please list your conflicts of interest

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
  - Industry Employee: 0 %
  - Company (one company): Medtronic, Philips, Boston scientific, Microport
  - Product or therapeutic area: None
  - <10 K€/year in total
  
- Payments to your institution (speaker fees, honoraria, advisory board fees, consultancy, activities executed by your department for the sponsor or investigator initiated and funded by an unconditional grant from the sponsor...)
  - Company (one company): none
  - Product or therapeutic area: none
  
- Receipts of royalties for intellectual property
  - Company (one company): none
  - Product or therapeutic area: none
  - none

**Add as many as necessary**

### **Position of influence declaration:**

- Nothing to declare
- More info at <https://www.escardio.org/The-ESC/About/Policies/esc-declaration-and-management-of-conflict-of-interest-policy>